Stoke Therapeutics’ (STOK) “Buy” Rating Reiterated at BTIG Research

Posted by Stanley Muller on May 11th, 2026

Stoke Therapeutics (NASDAQ:STOK – Get Free Report)‘s stock had its “buy” rating restated by stock analysts at BTIG Research in a research note issued to investors on Monday,Benzinga reports. They currently have a $39.00 target price on the stock. BTIG Research’s price target would suggest a potential upside of 18.58% from the company’s current price.

A number of other analysts have also issued reports on STOK. Wolfe Research started coverage on Stoke Therapeutics in a research note on Monday, February 23rd. They set an “outperform” rating and a $40.00 price objective on the stock. Guggenheim started coverage on Stoke Therapeutics in a research note on Thursday, February 5th. They set a “buy” rating and a $60.00 price objective on the stock. Wall Street Zen lowered Stoke Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 21st. Weiss Ratings reiterated a “hold (c)” rating on shares of Stoke Therapeutics in a research note on Friday, April 10th. Finally, Wedbush boosted their price objective on Stoke Therapeutics from $36.00 to $38.00 and gave the company an “outperform” rating in a research note on Tuesday, March 17th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Stoke Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $41.83.

Check Out Our Latest Stock Report on Stoke Therapeutics

Stoke Therapeutics Stock Performance

NASDAQ:STOK opened at $32.89 on Monday. Stoke Therapeutics has a 52-week low of $8.70 and a 52-week high of $40.22. The firm has a market cap of $2.05 billion, a price-to-earnings ratio of -11.70 and a beta of 1.20. The business’s fifty day moving average is $34.34 and its 200 day moving average is $32.03.

Stoke Therapeutics (NASDAQ:STOK – Get Free Report) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.79) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.80) by $0.01. Stoke Therapeutics had a negative return on equity of 51.16% and a negative net margin of 529.20%.The company had revenue of $6.23 million for the quarter, compared to analyst estimates of $6.48 million. Equities analysts predict that Stoke Therapeutics will post -3.41 EPS for the current fiscal year.

Insiders Place Their Bets

In other Stoke Therapeutics news, insider Barry Ticho sold 6,686 shares of the company’s stock in a transaction dated Wednesday, March 18th. The stock was sold at an average price of $31.34, for a total value of $209,539.24. Following the transaction, the insider directly owned 40,798 shares in the company, valued at $1,278,609.32. This represents a 14.08% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, General Counsel Jonathan Allan sold 4,628 shares of the company’s stock in a transaction dated Wednesday, March 18th. The stock was sold at an average price of $31.34, for a total value of $145,041.52. Following the completion of the transaction, the general counsel owned 28,836 shares in the company, valued at $903,720.24. This represents a 13.83% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 69,699 shares of company stock worth $2,526,714. 9.50% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Stoke Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the business. Dimensional Fund Advisors LP increased its position in shares of Stoke Therapeutics by 19.7% during the 1st quarter. Dimensional Fund Advisors LP now owns 989,936 shares of the company’s stock valued at $32,229,000 after purchasing an additional 162,797 shares during the last quarter. KBC Group NV bought a new position in shares of Stoke Therapeutics during the 1st quarter valued at about $36,000. Swiss National Bank increased its position in shares of Stoke Therapeutics by 4.5% during the 1st quarter. Swiss National Bank now owns 79,100 shares of the company’s stock valued at $2,575,000 after purchasing an additional 3,400 shares during the last quarter. Bank of New York Mellon Corp increased its position in shares of Stoke Therapeutics by 1.9% during the 1st quarter. Bank of New York Mellon Corp now owns 143,407 shares of the company’s stock valued at $4,669,000 after purchasing an additional 2,605 shares during the last quarter. Finally, Candriam S.C.A. increased its position in shares of Stoke Therapeutics by 12.4% during the 1st quarter. Candriam S.C.A. now owns 502,020 shares of the company’s stock valued at $16,346,000 after purchasing an additional 55,330 shares during the last quarter.

Stoke Therapeutics Company Profile

(Get Free Report)

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.